Progress for patients

Review the latest news on our company, products, and research

Image of light streams

June 4, 2022
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

June 3, 2022
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers

June 1, 2022
Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights

May 31, 2022
Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 26, 2022
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

May 18, 2022
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma with Updated Data from BCMA CAR-T Studies at 2022 ASCO and EHA

May 9, 2022
Legend Biotech Appoints Lori Macomber as Chief Financial Officer

May 6, 2022
Legend Biotech Announces Participation in Upcoming Investor Conferences

April 21, 2022
Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T

April 1, 2022
Legend Biotech Announces Appointment of Global Head of Research and Early Development

March 25, 2022
CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

March 23, 2022
Flanders Investment and Trade Names Legend Biotech Newcomer of the Year

March 18, 2022
Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

February 28, 2022
CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

February 18, 2022
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021

February 15, 2022
Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901

February 11, 2022
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen

January 4, 2022
Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference

December 30, 2021
Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors

December 16, 2021
Legend Biotech Corporation Announces Pricing of Public Offering

December 14, 2021
Legend Biotech Corporation Announces Proposed Public Offering

December 13, 2021
Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma

December 7, 2021
Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) Annual Meeting

December 7, 2021
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen

November 16, 2021
Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights

November 4, 2021
Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH

November 1, 2021
Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel

September 22, 2021
Legend Biotech to Host R&D Day on October 18, 2021

September 13, 2021
Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma

August 30, 2021
Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

August 23, 2021
Legend Biotech Reports Second Quarter 2021 Financial Results and Recent Highlights

June 22, 2021
Legend Biotech Announces Advancement of Global Manufacturing Infrastructure

June 01, 2021
Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings

May 26, 2021
U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma

May 25, 2021
Legend Biotech to Present at the Jefferies Virtual Healthcare Conference

May 18, 2021
Legend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights

May 12, 2021
Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings

April 30, 2021
Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

March 18, 2021
Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update

March 10, 2021
Legend Biotech Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call

Feburary 19, 2021
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2020

Feburary 01, 2021
Legend Biotech Announces BCMA CAR-T Therapy Cilta-cel Accepted for Accelerated Assessment in Europe for the Treatment of Relapsed and/or Refractory Multiple Myeloma

December 21, 2020
Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma

December 15, 2020
Legend Biotech to Participate in the 39th Annual J.P. Morgan Healthcare Conference

December 14, 2020
Legend Biotech Added to the NASDAQ Biotechnology Index

December 14, 2020
Legend Biotech Announces FDA Clearance of the IND for LB1901, an Investigational Autologous AntiCD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma

December 05, 2020
Legend Biotech Announces Phase 1b/2 Study Data of Cilta-cel, an Investigational BCMA CAR-T, Showing Early, Deep, and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma

December 03, 2020
Legend Biotech Announces Appointment of Dr. Patrick Casey to the Board of Directors

November 24, 2020
Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62nd American Society of Hematology (ASH) Annual Meeting

November 23, 2020
Legend Biotech Announces New Appointment to the Board of Directors and Resignation of Dr. Fangliang Zhang

November 16, 2020
Legend Biotech Reports Third Quarter 2020 Financial Results

November 09, 2020
Legend Biotech Announces Leadership Transition

November 05, 2020
Legend Biotech Announces ASH 2020 Data Presentations for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA CAR-T Cell Therapy in Development for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

September 28, 2020
Legend Biotech to Participate in the Jefferies Virtual Cell Therapy Summit

September 21, 2020
Legend Biotech Names Current Chief Financial Officer, Ying Huang, as Interim CEO

September 01, 2020
Legend Biotech to Participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference

August 28, 2020
Legend Biotech Reports Second Quarter 2020 Financial Results

August 05, 2020
The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell Therapy First investigational product being recommended for Breakthrough Therapy Designation in China

August 02, 2020
Legend Biotech Announces Chief Executive Officer Transition

August 02, 2020
Legend Biotech Announces Preliminary Results for First Half of 2020

June 09, 2020
Legend Biotech Announces Three New Appointments to the Board of Directors

June 09, 2020
Legend Biotech Corporation Announces Closing of Initial Public Offering

June 05, 2020
Legend Biotech Corporation Announces Pricing of Initial Public Offering

May 13, 2020
Updated Results from Phase 1b/2 Study of BCMA CAR-T Therapy JNJ-4528 Shows Early, Deep and Durable Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma

May 04, 2020
Legend Biotech and Noile-Immune Biotech Announce Collaborative Research and Licensing Agreement

Apr 01, 2020
Legend Biotech Raises $150.5 Million in Series A Preferred Financing To Advance its Oncology Pipeline and Platform

Mar 09, 2020
Legend Biotech Corporation Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Jan 28, 2020
Legend Biotech Announces Milestone Payment Achieved from the LCAR-B38M CAR-T Collaboration with Janssen

Dec 9, 2019
Updated Data from LEGEND-2, a Phase 1/2 Open-label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Long-term Responses, Safety Profile, and Complete Response Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myelomama

Dec 7, 2019
Initial Data from Phase 1b/2 Study of BCMA-Directed CAR-T Cell Therapy JNJ-4528 Show Early and High Responses in Advanced Relapsed or Refractory Multiple Myeloma

Dec 6, 2019
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for JNJ-68284528, an Investigational BCMA CAR-T Cell Therapy

Nov 6, 2019
Legend Biotech Announces Data Presentations at ASH 2019 for JNJ-4528/LCAR-B38M, an Investigational BCMA CAR-T Cell Therapy being Studied in Patients with Relapsed and/or Refractory Multiple Myeloma

Aug 5, 2019
Legend Biotech Announces Milestones Achieved from the LCAR-B38M CAR-T Collaboration with Janssen

Apr 15, 2019
New Data from LEGEND-2 Study of LCAR-B38M BCMA CAR-T Therapy Show High Overall Response in Patients with Advanced Relapsed or Refractory Multiple Myeloma

Apr 3, 2019
European Medicines Agency Grants Janssen PRIME Designation for JNJ-68284528 (LCAR-B38M), an Investigational BCMA CAR-T Therapy Discovered by Legend Biotech

Mar 5, 2019
Legend Biotech Ireland, Ltd. celebrates the official opening of its European headquarters in Dublin, Ireland

Feb 1, 2019
Legend Biotech USA, Inc. joins The American Society for Blood and Marrow Transplantation (ASBMTTM) Corporate Council

Dec 3, 2018
ASH 2018: Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma

Nov 14, 2018
Legend Biotech Chairman Frank Zhang awarded 2018 Person of the Year from China Healthcare Summit

May 30, 2018
Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple Myeloma

Mar 13, 2018
Nanjing Legend formally received the permission of a clinical trial granted by the CFDA with respect to LCAR-B38M CAR-T for autologous infusion

Dec 22, 2017
Legend Biotech Announces Closing of Global Strategic LCAR-B38M CAR-T Cell Immunotherapy Collaboration with Janssen

Dec 11, 2017
The application for investigational new drug by Nanjing Legend was accepted by the CFDA